Gastroenterology
Volume 135, Issue 5 , Pages 1442-1447 , November 2008

Current Directions in IBD Therapy: What Goals Are Feasible With Biological Modifiers?

  • William J. Sandborn

      Affiliations

    • Corresponding Author InformationAddress requests for reprints to: William J. Sandborn, MD, Mayo Clinic, 200 First Street SW, Rochester, MN 55905. fax: (507) 266-0335

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 The author discloses the following: Dr Sandborn is supported by Procter & Gamble Pharmaceuticals, Shire Pharmaceuticals, Centocor, Abbott Laboratories, UCB Pharma. Dr Sandborn is a consultant for Procter & Gamble Pharmaceuticals, Shire Pharmaceuticals, Salix Pharmaceuticals, Centocor, Abbott Laboratories, UCB Pharma, and Elan.

PII: S0016-5085(08)01784-8

doi: 10.1053/j.gastro.2008.09.053

Gastroenterology
Volume 135, Issue 5 , Pages 1442-1447 , November 2008

Article Tools

* Image Usage & Resolution